The total value of the offer based on all outstanding shares in Abliva amounts to approximately SEK 725.3 million (USD 66.1 million). The three major shareholders of Abliva, holding in aggregate approximately 49.82 percent of the total number of shares and votes in Abliva, have undertaken to accept the offer, subject to customary conditions.
Pharming Group N.V. is a global biopharmaceutical company dedicated to transforming the lives of patients with rare, debilitating, and life-threatening diseases. Pharming is commercialising and developing an innovative portfolio of protein replacement therapies and precision medicines, including small molecules and biologics. Pharming is headquartered in Leiden, the Netherlands, and has employees around the globe who serve patients in over 30 markets in North America, Europe, the Middle East, Africa, and Asia-Pacific. Pharming’s ordinary shares are traded on Euronext Amsterdam and its ADSs are traded on the Nasdaq Global Market.
Abliva discovers and develops medicines for the treatment of mitochondrial disease. This rare and often very severe disease occurs when the cell’s energy provider, the mitochondria, do not function properly. The company has prioritised two projects. KL1333, a powerful regulator of the essential co-enzymes NAD⁺ and NADH, has entered late-stage development. NV354, an energy replacement therapy, has completed preclinical development. Abliva, based in Lund, Sweden, is listed on Nasdaq Stockholm, Sweden.
The NautaDutilh team consisted of Willem Bijveld, Dineth de Graaf, Jafar Alhashime, Annefleur van Oel, Auke Knigge, Petra Zijp, Victorine Dijkstra, Céline Hennink, Lauren Delleman, Nicoline Welzenbagh, and Jinne van Belle.
